<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CD19 CAR T cell therapy response &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/cd19-car-t-cell-therapy-response/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 18 Jun 2025 20:40:43 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>CD19 CAR T cell therapy response &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Scientists Uncover B-Cell Lymphoma Characteristics Predicting Optimal Response to CD19 CAR T Cell Therapy</title>
		<link>https://bioengineer.org/scientists-uncover-b-cell-lymphoma-characteristics-predicting-optimal-response-to-cd19-car-t-cell-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 18 Jun 2025 20:40:43 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CD19 CAR T cell therapy response]]></category>
		<category><![CDATA[large B-cell lymphoma]]></category>
		<category><![CDATA[precision oncology strategies]]></category>
		<category><![CDATA[single-cell profiling]]></category>
		<category><![CDATA[tumor microenvironment subtypes]]></category>
		<guid isPermaLink="false">https://bioengineer.org/scientists-uncover-b-cell-lymphoma-characteristics-predicting-optimal-response-to-cd19-car-t-cell-therapy/</guid>

					<description><![CDATA[In an unprecedented advancement in lymphoma research, scientists at The University of Texas MD Anderson Cancer Center have unveiled a groundbreaking study that distinguishes three distinct microenvironmental subtypes within large B-cell lymphoma (LBCL) tumors. These classifications illuminate the varying degrees of patient responsiveness to CD19-targeted chimeric antigen receptor (CAR) T cell therapy, a form of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">249827</post-id>	</item>
	</channel>
</rss>
